Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · Real-Time Price · USD
110.34
-2.20 (-1.95%)
Sep 16, 2025, 2:30 PM EDT - Market open
-1.95%
Market Cap136.91B
Revenue (ttm)28.86B
Net Income (ttm)6.31B
Shares Out 1.24B
EPS (ttm)5.01
PE Ratio22.03
Forward PE13.13
Dividend$3.16 (2.86%)
Ex-Dividend DateSep 15, 2025
Volume2,736,804
Open113.22
Previous Close112.54
Day's Range110.75 - 114.13
52-Week Range81.83 - 121.83
Beta0.38
AnalystsBuy
Price Target116.36 (+5.46%)
Earnings DateNov 5, 2025

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,600
Stock Exchange NASDAQ
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial Statements

Analyst Summary

According to 23 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $116.36, which is an increase of 5.46% from the latest price.

Price Target
$116.36
(5.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference 2025 September 10, 2025 11:25 AM EDT Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Part...

6 days ago - Seeking Alpha

Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Daniel O'Day - Chairman & CEO Johanna Mercier - Chief C...

7 days ago - Seeking Alpha

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief...

12 days ago - Business Wire

US plans to bring Gilead HIV drug to market in high-burden HIV countries

The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over thre...

12 days ago - Reuters

Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Andrew Dickinson - Chief Financial Officer Conference Call P...

12 days ago - Seeking Alpha

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HI...

12 days ago - Business Wire

Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Dietmar Berger - Chief Medical Officer Conference Call Participants Ca...

13 days ago - Seeking Alpha

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

13 days ago - Reuters

Gilead starts building manufacturing hub under $32 billion planned US investments

Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, as part of its planned $32 billion inves...

13 days ago - Reuters

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTD...

13 days ago - Business Wire

Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales

Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves comp...

14 days ago - Seeking Alpha

EU approves Gilead's new injection for preventing HIV

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.

21 days ago - Reuters

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's...

21 days ago - Business Wire

Gilead unit to acquire cell therapy developer Interius for $350 million

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver...

26 days ago - Reuters

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.

Other symbols: CVS
26 days ago - Benzinga

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

26 days ago - Business Wire

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV...

26 days ago - Seeking Alpha

Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic...

Other symbols: CVS
26 days ago - Reuters

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthc...

26 days ago - Business Wire

Our Top 10 High Growth Dividend Stocks - August 2025

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...

Other symbols: APHAVGOBBVABKEMEFIXHWM
4 weeks ago - Seeking Alpha

Final Trade: BSY, GDX, MNDY, GILD

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: GDXMNDYBSY
5 weeks ago - CNBC Television

Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook

Gilead Sciences' stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company's HIV franchise is not only holding firm but expanding, with its new p...

5 weeks ago - Invezz

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences GILD announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

5 weeks ago - Benzinga

These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences

A flurry of company earnings led to big stock moves early Friday.

Other symbols: EXPEPINSTTDTWLO
5 weeks ago - Barrons

Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew D. Dickinson - Chief Financial Officer Daniel P.

5 weeks ago - Seeking Alpha